

Neuroscience of Addiction: Relevance to Prevention and Treatment

Nora D. Volkow, M.D., Maureen Boyle, Ph.D.

Addiction, the most severe form of substance use disorder, is a chronic brain disorder molded by strong biosocial factors that has devastating consequences to individuals and to society. Our understanding of substance use disorder has advanced significantly over the last 3 decades in part due to major progress in genetics and neuroscience research and to the development of new technologies, including tools to interrogate molecular changes in specific neuronal populations in animal models of substance use disorder, as well as brain imaging devices to assess brain function and neurochemistry in humans. These advances have illuminated the neurobiological processes through which biological and sociocultural factors contribute to resilience against or vulnerability for drug use and addiction. The delineation of the neurocircuitry disrupted in addiction, which includes circuits

that mediate reward and motivation, executive control, and emotional processing, has given us an understanding of the aberrant behaviors displayed by addicted individuals and has provided new targets for treatment. Most prominent are the disruptions of an individual's ability to prioritize behaviors that result in long-term benefit over those that provide short-term rewards and the increasing difficulty exerting control over these behaviors even when associated with catastrophic consequences. These advances in our understanding of brain development and of the role of genes and environment on brain structure and function have built a foundation on which to develop more effective tools to prevent and treat substance use disorder.

Am J Psychiatry 2018; 175:729–740; doi: 10.1176/appi.ajp.2018.17101174

Drug overdoses claimed more than 63,300 American lives in 2016 (1), and excessive alcohol use and tobacco use are estimated to contribute to 88,000 (2) and 480,000 (3) deaths each year, respectively. More than 20 million Americans suffer with substance use disorder,

and overdose deaths represent only a fraction of the resultant health consequences. For example, the rate of emergency department visits from opioid-related overdoses or accidents is 20 times greater than the rate of opioid overdose death (4). Of every 1,000 babies born, six have neonatal abstinence syndrome (5) and up to nine have fetal alcohol spectrum disorders (6). Yearly there are approximately 30,500 new cases of hepatitis C (7), a virus transmitted by injection drug use. The combined consequences of drug use and addiction also have enormous economic consequences, which include an estimated cost of \$249 billion from alcohol (8), \$300 billion from tobacco (3), and \$193 billion from other drugs (9). And while research has identified many evidence-based prevention and treatment strategies that could help reduce alcohol use and drug use and their

consequences, these interventions are highly underutilized and not effective for everyone.

Our deepening understanding of the neurobiological, genetic, epigenetic, and environmental mechanisms underlying addiction is helping

researchers identify new targets for prevention and treatment interventions. In addition, advancing technologies—from gene sequencing and manipulation, to increasingly more sensitive imaging technologies, to brain stimulation devices, to information technologies and mobile health tools—are producing unprecedented capacity to interrogate addiction and its causes. This growing knowledge base offers unique opportunities for translation of substance use disorder prevention and treatment strategies.

NEUROBIOLOGY OF ADDICTION RISK

The risk for addiction is related to complex interactions between biological factors (genetics, epigenetics, developmental attributes, neurocircuitry) and environmental factors

AJP AT 175

Remembering Our Past As We Envision Our Future

August 1956: Management of the Narcotic Addict in an Outpatient Clinic

Benjamin Boshes et al.: "The question of why some drug users become addicted and others do not is one which has defied understanding."

(Am J Psychiatry 1956; 113:158–162)

(social and cultural systems, stress, trauma, exposure to alternative reinforcers). Research has started to uncover how psychological traits, emotions, and behaviors are encoded in the brain; how environmental factors influence brain circuits and subsequent behavior; and how genetic and epigenetic factors influence the development and functioning of the brain, all of which are of relevance to addiction risk and resilience.

Genetic factors account for approximately half of the risk for addiction (10). Thus far, most genes implicated in this risk largely influence an individual's biological response to substances of abuse or their metabolism (11). Genetic findings have also provided new insight into the neurobiology of addiction. For example, a variant in the gene encoding for the alpha 5 subunit of the nicotinic receptor, which is highly expressed in the habenula, has been consistently associated with higher vulnerability to nicotine addiction (12, 13). This discovery brought attention to the importance of the mid-brain habenula-interpeduncular axis in nicotine dependence and withdrawal (14). Further, studies in transgenic mice have documented that the alpha 5 polymorphism influences the firing pattern of pyramidal neurons in the prefrontal cortex in a way that could help explain the greater vulnerability for smoking among patients with schizophrenia (15). Ongoing research aims to identify how genes mediate the development of the human brain and the subsequent sensitivity of the brain to environmental factors that influence the risk for substance use disorder.

Epigenetic factors, which orchestrate gene expression and silencing, have been implicated in the long-lasting neuroplastic changes associated with drug taking in animal models of addiction (16), regulating pathways through which environmental risk factors, such as stress, influence biological drivers of substance use and addiction (17). For example, early life stress can influence the development of the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased reactivity to stress and susceptibility to addiction. Interestingly, preclinical studies have identified transgenerational epigenetic effects of parental drug taking prior to conception on addiction-related behavior in offspring (18, 19), though such transgenerational effects have not been demonstrated yet in humans.

Characterization of human neurodevelopment has allowed us to understand why adolescents are more likely than adults to experiment with drugs and to develop substance use disorders. This understanding in part reflects the fact that the adolescent brain has not completed its development and is more neuroplastic than the adult brain. The human brain continues to develop until the early to mid-20s, and the rate of development differs across neuronal circuits, with development occurring faster for reward/motivation and emotional circuits than for prefrontal top-down control circuits, which are among the last to develop (20). As a result, during adolescence, the striatal reward/motivation and limbic-emotional circuits are hyperactive, leading to greater emotional reactivity and reward-seeking behaviors.

Moreover, the prefrontal cortex cannot fully self-regulate, leading to more impulsivity and risk taking (21). Early exposure to drugs of abuse may further impair the development of the prefrontal cortex, increasing the long-term risk for addiction (16). The increased neuroplasticity of the adolescent brain explains why addiction develops faster in an adolescent than in an adult (22), and it also explains the greater sensitivity of adolescents to environmental stimuli, such as stress, that influence drug taking (23, 24). Similarly, studies have started to assess the effects of social stressors on development of the human brain, and these studies are relevant for understanding why social stressors increase the risk for substance use disorder and other mental illnesses. For example, studies evaluating the effects of social deprivation during infancy and early childhood have reported delayed maturation that results in impaired brain connectivity, which could underlie increased impulsivity in these children (25). Importantly, preliminary studies have reported that interventions that provide social support and care may be able to reverse some of these impairments (26).

Multiple psychological traits have also been shown to influence risk for addiction, including impulsivity, novelty and sensation seeking, and stress reactivity (27). Neuroscience has started to delineate the brain circuits that mediate these traits. For example, trait impulsivity is associated with dysregulation of corticostriatal circuits as well as altered activation of, and functional connectivity between, the anterior cingulate cortex and amygdala (28). High sensation seeking has been associated with reduced thickness of the anterior cingulate cortex and middle frontal gyrus (29), as well as altered midbrain volumes (30). Stress reactivity is correlated with prefrontal corticolimbic regulation of HPA axis activity (31). Understanding the neurobiological basis of traits that influence risk for substance use disorder may lead to development of biomarkers that can be used to target prevention interventions for individuals at high risk. Furthermore, this knowledge will facilitate the development of strategies to strengthen specific circuits to improve resilience and support recovery.

NEUROBIOLOGY OF THE ADDICTED BRAIN

Brain imaging research has helped map the neuronal circuits that mediate the relapsing pattern of addictive behaviors, including rewarding responses during intoxication, conditioning to the drug and its cues, negative mood and increased stress reactivity during drug withdrawal, and drug craving during exposure to cues or stressors (32).

During intoxication, the drug stimulates large bursts of dopamine in the mesolimbic reward system (the nucleus accumbens and dorsal striatum) that reinforce drug taking (bingeing) (33) and strengthen conditioned associations, which link stimuli that precede drug consumption with the expectation of reward (34). Counterintuitively, in a person suffering from addiction, the drug-induced dopamine increases are attenuated, an effect that has been observed in

both human subjects and animal models (35–37). In humans, the attenuated dopamine response to the drug is associated with reduced subjective experience of reward during intoxication (37). While major emphasis has been placed on the dopaminergic system in explaining the rewarding and reinforcing effects of drugs, it is also clear that other neurotransmitters, including opioids, cannabinoids, GABA, and serotonin—to a greater or lesser extent, depending on the pharmacological characteristics of the drug—contribute to the pleasurable or euphorogenic responses to drugs and to the neuroadaptations that result in addiction (38).

As the intoxicating effects of a drug wear off, an addicted individual enters the withdrawal phase, which is associated with negative mood, including anhedonia, increased sensitivity to stress, and significant dysphoria and anxiety. Such a response is not typically observed in an individual with short drug exposure history, and the duration of exposure needed for a response to emerge varies for the different types of drugs, with opioids producing these effects particularly rapidly. The circuits underlying the withdrawal phase comprise basal forebrain areas, including the extended amygdala as well as the habenula, and implicate neurotransmitters and neuropeptides such as corticotropin-releasing factor (CRF), norepinephrine, and dynorphin (39, 40). Increased signaling in these circuits triggers aversive symptoms that render the individual vulnerable to cravings and preoccupation with taking the drug as means to counteract this aversive state. In parallel, the dopamine reward/motivation system is hypo-functional, contributing to anhedonia and the aversive state during withdrawal (41).

During the craving stage, the conditioned stimuli (drug cues) themselves elicit dopamine release in the striatum, triggering the motivation to seek and consume the drug (42). This phase also involves prefrontal circuits, including the orbitofrontal and anterior cingulate cortex, which underlie salience (or value) attribution (43), as well as circuits in the hippocampus and amygdala, which mediate conditioned responses (44). Glutamatergic projections from these regions to the ventral tegmental area and striatum modulate the sensitivity and reactivity to cues and to adverse emotions that trigger the urgent motivation for, and preoccupation with, drug taking (32).

In a brain not affected by addiction, the circuits controlling desire for a drug are held in check by prefrontal cortical regions that underlie executive functions, which support making rational, healthy decisions, and that regulate emotions. Thus, the awareness that a drug will provide an immediate reward is balanced by consideration of long-term goals, and the individual is able to make a reasonable choice and carry it through. However, when the prefrontal cortical circuits underlying executive functions are hypo-functional—as a result of repeated drug exposure or from an underlying vulnerability—and the limbic circuits underlying conditioned responses and stress reactivity are hyperactive—as a result of drug withdrawal and long-term neuroadaptations that downregulate sensitivity to nondrug

rewards—the addicted individual is at a tremendous disadvantage in opposing the strong motivation to take the drug. This explains the difficulty addicted individuals face when trying to stop taking drugs even when they experience negative consequences and have become tolerant to the drug's pleasurable effects.

The delineation of the various brain circuits and neurotransmitters (dopamine, glutamate, dynorphin, enkephalin, GABA, serotonin) that contribute to addiction has helped identify potential targets for addiction treatment (see below). For example, in animal models, interventions to enhance dopamine signaling through D₂ receptors, which are downregulated in addiction and are associated with impaired prefrontal activity, reduce compulsive drug taking (41). In addition, interventions that counteract the enhanced reactivity of glutamatergic projections from the prefrontal cortex and amygdala to the ventral tegmental area and striatum have been shown to prevent drug taking following exposures to cues or stressors (45), and those that counteract the negative mood during the withdrawal state (CRF or kappa antagonists) can prevent escalation of drug use (46, 47).

In developing new strategies to prevent and treat substance use disorder, it is also important to recognize the high rate of comorbidity with mental illness (48–50). Patients with these comorbidities often have more severe and treatment-resistant disorders compared with patients who have either disorder alone (49, 51). Many overlapping brain regions and circuits (49, 50, 52, 53)—including those that mediate reward, executive function, and emotions—and neurotransmitter systems—including dopamine (54–56), serotonin (57, 58), glutamate (59, 60), GABA (61), and norepinephrine (56, 62, 63)—have been implicated in substance use disorder and other mental illnesses. There is also overlap in the genetic and environmental risk factors for these disorders. Genes that influence stress reactivity, risk taking, and novelty-seeking behaviors can influence the initiation of substance use as well as the development of substance use disorder and other mental illnesses. And environmental factors such as chronic stress, trauma, and adverse childhood experiences increase risk for both substance use disorder and mental illness (49, 64).

ACCELERATING DEVELOPMENT OF NEW PREVENTION INTERVENTIONS

There are several evidence-based prevention interventions for substance use disorder that have been developed on the basis of epidemiological data identifying factors that increase risk for or provide resilience against substance use disorder (Table 1).

Our increased understanding of the effects of substance use on normal brain development, the deleterious effects of adverse environments, and the role of innate vulnerabilities will allow for the development of personalized intervention to reverse or mitigate some of these deficits. For example, adverse social environments during early childhood can

TABLE 1. Strategies for Prevention of Substance Use Disorder^a

| Modifiable Risk Factor | Intervention | Domain | Protective Factor |
|-----------------------------------|---|----------------------|--|
| Early aggressive behavior | Self-regulation skills training | Individual | Self-control |
| Poor social skills | Social skills training | Individual | Positive relationships |
| Exposure to stress | Stress resilience training | Family or community | Resilience to stress |
| Insufficient parental supervision | Parenting skills training | Family | Parental monitoring and support |
| Low self-confidence | Educational interventions; tutoring | Family or schools | Academic success |
| Early substance use | Early prevention interventions | Individual | Delayed initiation |
| High drug availability | Supply reduction policies; community policing | Community or schools | Low drug availability |
| Misperceptions of drug use norms | Norms training | Community or schools | Knowledge that majority do not use drugs |
| Peer substance use | Refusal skills training | Community or schools | Non-substance-using peers |
| Permissive drug culture | Community-level interventions | Community or schools | Social norms rejecting substance misuse |
| Poverty | Jobs training; community-building interventions | Societal | Economic opportunity |

^a Strategies include decreasing risk factors and enhancing protective factors at the individual, family, community or school, and societal levels. Modified from reference 65.

result in delayed prefrontal limbic connectivity (25), which is associated with impulsivity (66). In turn, impulsivity predicts greater vulnerability for substance use disorder (67). However, children can be trained to improve their self-regulation and hence control impulsivity (68). Furthermore, social isolation and exposure to social environments with limited support are associated with reduced dopamine D₂ receptor expression in the striatum, which is linked with greater vulnerability for impulsivity and compulsive drug use (69–71). Research is also starting to identify changes in brain development triggered by early exposure to drugs, including alcohol and marijuana (72, 73). Future access to standardized measures of brain development will support the development of early interventions to mitigate developmental vulnerabilities or counteract negative neuroadaptations. In this respect, the recently launched Adolescent Brain Cognitive Development Study, which aims to study 10,000 children with brain imaging, genotyping, and deep phenotyping across the transition from childhood into adulthood, will provide valuable data for determining normal human variability in brain development and how it is disrupted by drug use and mental illnesses (74). Similarly, the Baby Connectome Project, a study of brain development in children from birth through 5 years of age (75), will provide insight into the early development of the human brain at a stage when it is most sensitive to adverse environmental effects, such as neglect and abuse.

ACCELERATING DEVELOPMENT OF NEW TREATMENTS

The substance use disorder treatment field has seen some important successes, but therapeutic options are still limited. Although the Food and Drug Administration (FDA) has approved medications for the treatment of opioid, alcohol, and tobacco use disorders (Table 2) (77), which represent meaningful advances in therapeutics for addictions, they are

not effective for all patients. Similarly, while evidence-based psychosocial treatments (e.g., cognitive-behavioral therapy, contingency management interventions) are available for substance use disorder, their effectiveness is also limited (78).

Most pharmaceutical companies have been reticent to invest in addiction due in part to stigma (79) as well as to perceptions that the market is small, that executing clinical trials in patients with substance use disorders is difficult (because of frequent comorbidities, criminal or legal problems, and poor adherence to treatment protocols), and that the regulatory bar required for FDA approval is too high (i.e., abstinence—discussed below [80]). These factors represent a major challenge in medication development. Consequently, the National Institute on Drug Abuse (NIDA) has focused on partnering with industry to encourage drug development by identifying promising targets and funding research to lessen risks associated with drug development. Examples of such partnerships include helping in the development of medications to treat opioid use disorders, such as a buprenorphine/naloxone combination (Suboxone) (81), a 1-month extended-release naltrexone (Vivitrol), a 6-month buprenorphine subdermal implant (Probuphine) (82), and a “user-friendly” intranasal opioid overdose naloxone formulation (Narcan Nasal Spray) (83). The current opioid crisis has further highlighted the urgency for greater participation of industry in medication development (84).

In parallel, research is ongoing to translate basic knowledge about the molecular pathways and brain circuits involved in substance use disorders into new treatments. A promising strategy explores the use of pharmacotherapies that target endophenotypes associated with addiction—for example, using cognitive enhancers to improve impulse control, planning, and decision making (85–87), and using medications to reduce stress reactivity and dysphoria to prevent relapses (88, 89). As discussed above, various neurotransmitter systems are involved in such cognitive and emotional functions and represent potential therapeutic targets.

TABLE 2. Medications for Addiction Treatment^a

| Medication | Use | Formulations | DEA Schedule |
|--------------------------------|--|---|---------------|
| Buprenorphine/naloxone | Opioid use disorder | Sublingual or buccal film Sublingual tablet (76) | III |
| Buprenorphine | Opioid use disorder | Sublingual tablet 6-month buprenorphine subdermal implant 1-month extended-release buprenorphine injection ^b | III |
| Methadone | Opioid use disorder | Tablet Oral solution Injection | II |
| Naltrexone | Opioid use disorder; alcohol use disorder | Tablet Extended-release injectable | Not scheduled |
| Acamprosate | Alcohol use disorder | Delayed-release tablet | Not scheduled |
| Disulfiram | Alcohol use disorder | Tablet | Not scheduled |
| Nicotine replacement therapies | Nicotine addiction | Transdermal patches Gum Lozenges Inhalers Nasal spray | Not scheduled |
| Bupropion | Nicotine addiction | Tablet | Not scheduled |
| Varenicline | Nicotine addiction | Tablet | Not scheduled |

^a Modified from reference 65. DEA=Drug Enforcement Administration.

^b One-week buprenorphine injection is being evaluated by the Food and Drug Administration.

Another strategy involves “repurposing” medications already approved for other indications. Because there is overlap in the neuropathology and symptomatology between substance use disorder and other mental illnesses (see the section “Neurobiology of the Addicted Brain”), and many of the medications used to treat mental illnesses bind to multiple therapeutic targets (90), some of these may be beneficial for substance use disorders. The medications’ existing safety profiles and pharmacology data shorten the timeline for obtaining FDA approval if the drugs are found effective for treating substance use disorders. A notable example is bupropion, which was originally developed as an antidepressant and was subsequently found to be clinically useful in smoking cessation (91).

Although there is only one approved drug combination for substance use disorders (i.e., the buprenorphine/naloxone combination), the few studies evaluating other drug combinations have shown promising results. For example, the combination of buprenorphine with naltrexone not only decreased cocaine use in individuals with dual cocaine and heroin use disorders (92) but also reduced heroin use to a greater extent than buprenorphine alone (93). Similarly, the combination of lofexidine and dronabinol reduced symptoms of cannabis withdrawal significantly more than either medication alone (94).


Research is also ongoing to define endpoints other than abstinence for measuring treatment efficacy, such as clinically meaningful reductions in drug use associated with improvements in health outcomes (95). Such adjustments could reduce the regulatory bar for obtaining FDA approval for new therapeutics. For example, research has indicated that reduced use of cocaine led to decreased endothelial

dysfunction, a marker of heart-disease risk associated with chronic cocaine use (96). Importantly, there is precedent for alternative endpoints: the FDA has approved the use of percentage of subjects with no heavy drinking days as an outcome for alcohol use disorder. This measurement is sensitive for detecting differences between medication and placebo, and allowing some days of consumption increases the effect size (97). In the case of opioid use disorders, a relevant endpoint could be overdose prevention; recently, a study on parolees found reduced overdoses were associated with extended-release naltrexone (98).

Promising Pharmacological Targets

The preclinical literature includes a wide range of promising strategies for substance use disorders that aim either at the main protein target of specific drugs, at modulators of the brain reward system, or at modulators of downstream circuits disrupted in addiction (Figure 1).

Therapeutic strategies that target the mu-opioid receptor have been most effective for opioid use disorders and are being pursued in the development of nonaddictive analgesics, which could help reduce the risk of addiction as an unintended consequence of pain management (84). In this respect, the recent identification of the structure of the mu-opioid receptor has provided novel insights into mechanisms of tolerance and is facilitating development of medications that target specific intracellular signaling pathways of the mu-opioid receptor, referred to as biased agonists. Biased opioid agonists that are developed as analgesics target the G-coupled protein “G_i” intracellular pathway, which is believed to underlie analgesia, while not engaging the β-arrestin pathway, which is associated with tolerance and

FIGURE 1. The Three Stages of the Addiction Cycle and the Main Brain Regions Implicated^a

^aPotential medication targets and therapeutic strategies that target each stage are listed. KOR=kappa-opioid receptor; NK1=neurokinin 1; tDCS=transcranial direct current stimulation; TMS=transcranial magnetic stimulation. Modified from reference 65.

the respiratory-depressing effects of opioid agonists (99). Phase 3 clinical testing of a mu-opioid receptor biased agonist (TRV130) is under way (100, 101). In addition, the orvinol analogue BU08028, a compound similar to buprenorphine, has been shown to be a safe opioid analgesic without abuse liability in nonhuman primates (102). Research into these and other opioids (103) is poised to lead to improved treatments for opioid use disorders and pain.

Novel pharmacological approaches for treating opioid use disorders that do not involve the mu-opioid receptor include strategies to modulate the reward circuit via antagonism of the neurokinin 1 receptor (104) and to counteract withdrawal via antagonism of the kappa-opioid receptor (89). Lofexidine, an α_{2A} -adrenergic receptor agonist originally developed as an antihypertensive, also decreases opioid withdrawal symptoms and is undergoing NIDA-funded trials (105, 106). Another promising medication is lorcaserin, a selective 5-HT_{2C} receptor agonist already FDA-approved for weight loss that reduces opioid seeking in rodent models (107).

Oxytocin, a neuropeptide known for its role in social bonding, is also of interest for substance use disorder. Oxytocin-expressing neurons project to brain regions implicated in reward (including the ventral tegmental area and nucleus accumbens) (108, 109) and stress (including the amygdala and hippocampus) (108, 109). Preclinical studies have shown that oxytocin decreases self-administration of heroin (110), cocaine (111, 112), methamphetamine (113), and alcohol (114–116) and also alleviates nicotine withdrawal (117). Oxytocin treatment during adolescence also reduced methamphetamine (118) and alcohol (119) seeking in adult

rodents. In addition, oxytocin reduced reinstatement of drug seeking in rodents in response to triggers of drug craving for methamphetamine (120–122) and cocaine (112, 123, 124). In humans, intranasal oxytocin reduces cue-induced craving for nicotine (125), stress-induced craving for marijuana (126), and withdrawal and anxiety symptoms.

Cannabinoids may also be useful for treating substance use disorders, and identifying medications that target the endocannabinoid system without producing cognitive impairment and rewarding effects could lead to new treatments for substance use disorders. For example, dronabinol (a synthetic tetrahydrocannabinol [THC] formulation approved for AIDS-related anorexia and chemotherapy-related nausea) reduced withdrawal symptoms associated with cannabis use disorder (127), and nabilone (a synthetic cannabinoid similar to THC) reduced cannabis withdrawal- and relapse-related measures in human laboratory studies (128). In addition, a study of nabiximol (an oral mucosal spray containing a THC-to-cannabidiol [CBD] ratio of 1:1) found reductions in severity and duration of cannabis withdrawal and increased retention in treatment (129). Finally, an ongoing randomized clinical trial will evaluate whether CBD (Epidiolex), when added to medical management, can improve treatment outcomes for cannabis use disorders (130).

The body's endogenous cannabinoids (anandamide and 2-arachidonoylglycerol, or 2-AG, which interact with cannabinoid receptors CB1R and CB2R) optimize the inhibitory and excitatory balance in the brain in a state-dependent manner (131), so side effects might occur with orthosteric ligands that either activate (e.g., dronabinol) or block (e.g.,

rimonabant) CB1R broadly. For example, rimonabant, which showed efficacy in treating obesity and inhibiting the rewarding effects of cannabis, was also associated with negative affect and suicidal ideation (132). Instead, the manipulation of cannabinoid receptors (CB1R or CB2R) via allosteric modulators, which simply enhance or inhibit receptor responses to endocannabinoids, maintaining the state dependence of the endocannabinoid system, may be more promising for medication development. Although the development of CB1R allosteric modulator medications is in its infancy (133), the negative allosteric modulator pregnenolone appears to protect against the intoxicating effects of THC (134) and is being evaluated for the treatment of cannabis use disorder. In addition, the positive allosteric CB1R modulator ZCZ011 has antinociceptive effects without being reinforcing (135) and thus holds potential as a nonaddictive analgesic.

Other endocannabinoid system modulators being evaluated for cannabis use disorder include specific inhibitors of fatty acid amide hydrolase or of monoglycerol lipase, which slow the breakdown of endocannabinoids, as these compounds may reduce withdrawal symptoms and/or may lead to new nonaddictive analgesics (136, 137).

Stimulant use disorders have been among the most challenging for therapeutics development. The most investigated strategy has been the use of longer-acting stimulant medications (e.g., methylphenidate and amphetamines) for cocaine addiction. Many of these studies have failed to reach significant positive outcomes, except in individuals with comorbid attention deficit hyperactivity disorder. However, a meta-analysis reported evidence of mild benefit for the use of amphetamines in cocaine addiction (138). Similarly, modafinil, a medication used for narcolepsy that has mild stimulant properties (139), has been shown by some studies to be beneficial for the treatment of cocaine addiction (140), though not by others (141). A different approach, based on studies documenting that enhanced glutamatergic signaling from limbic and ventral prefrontal regions can drive cue-induced cravings and relapse (142), targets medications that can help restore balance to these glutamatergic projections. For example, *N*-acetylcysteine, which helps modulate glutamate signals by activating the cystine-glutamate exchange and thereby stimulating extrasynaptic metabotropic glutamate receptors (143), decreases cocaine seeking in animal models (144). *N*-acetylcysteine is well tolerated in cocaine-dependent individuals and may reduce cocaine-related withdrawal symptoms and craving (145). A clinical trial did not find *N*-acetylcysteine to be effective for patients actively using cocaine; however, *N*-acetylcysteine reduced cravings and prevented relapse in patients who had achieved abstinence (146). The efficacy of *N*-acetylcysteine is limited by low bioavailability and poor permeability of the blood-brain barrier. Similar compounds with greater potency and bioavailability, such as *N*-acetylcysteine amide, may prove more effective (147).

Strategies to deliver degradative enzymes have also been proposed for cocaine use disorders, and research is ongoing to

develop stable, long-lasting forms of cocaine-degrading enzymes, including cocaine esterase, cocaine hydrolase (148–151), and butyrylcholinesterase (152). Preclinical evidence has shown that these fusion proteins increase cocaine's metabolism (153, 154). However, clinical studies have failed to show efficacy (152).

Antiepileptic drugs have also been evaluated in the management of substance use disorder. A proposed mechanism for their benefit is that in cocaine use disorders, and in other substance use disorders, dysfunction of GABA-ergic signaling contributes to drug taking (155, 156). Gabapentin, a widely prescribed anticonvulsant and pain medication, has shown some benefits in the treatment of alcohol use disorders (157) and might reduce cannabis use and withdrawal symptoms in cannabis use disorders. Topiramate is an antiepileptic medication (158) for which there is preliminary clinical evidence of reduced cocaine use and improved outcomes in cocaine-dependent individuals (159). In methamphetamine users, topiramate reduced the amount of drug taken by patients with an active use disorder and reduced relapse rates among those in recovery (160).

Promising Nonpharmacological Therapies

Alternative nonpharmacological strategies include vaccines and other biologics (i.e., monoclonal antibodies and gene-delivery strategies); neural stimulation technologies, such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), deep-brain stimulation, and peripheral stimulation devices; and behavioral interventions.

Biological therapeutics. Vaccines and passive immunization with antibodies work by binding to the drug in the blood and preventing it from entering the brain. Preclinical studies have shown encouraging results for vaccines against prescription opioids, heroin, and fentanyl, inducing high-titer antibody responses to opioids (161–163). Clinical studies both with cocaine and nicotine vaccines have resulted in insufficient antibody titers in humans, and further work is needed (164–166).

A similar approach involves passive immunization, or treating patients with monoclonal antibodies. Monoclonal antibodies can be delivered in high concentrations, and the dosing can be more precisely controlled than with vaccines. An anti-methamphetamine monoclonal antibody (ch-mAb7F9) was found to be safe and well tolerated in phase 1 trials (167). Research is ongoing to develop monoclonal antibodies for fentanyl, nicotine, and cocaine (168, 169). Production of long-lasting monoclonal or polyclonal antibodies against very potent synthetic opioids (e.g., fentanyl and its analogs) could be beneficial to prevent relapse and help prevent overdoses, which are currently driving increases in fatalities in the United States (1, 170).

Brain and peripheral stimulation therapeutics. The identification of the neuronal circuits affected in addiction can also suggest therapeutic targets for brain stimulation strategies, such as TMS and tDCS. Examples include the strengthening

of prefrontal activity to improve self-regulation or the modulation of limbic pathways to reduce incentive salience and cravings.

TMS uses repetitive pulses of a magnetic field, and tDCS uses weak electrical currents through electrodes placed on the scalp to modulate the activity of targeted brain regions. Preliminary clinical trials have reported positive results with TMS for the treatment of nicotine, alcohol, and cocaine use disorders and with tDCS for nicotine, alcohol, cocaine, methamphetamine, opioid, and cannabis use disorders, with reductions in cravings, use, or both reported (171–173). Most studies have targeted the dorsolateral prefrontal cortex, although some studies have targeted the anterior cingulate cortex, the insular cortex, the frontal-parietal-temporal area, and the ventromedial prefrontal cortex. The small sample sizes, short durations, and heterogeneity in technical protocols (e.g., frequency, duration, hemisphere targeted) limit the conclusions that can be drawn. However, existing research suggests these technologies have significant potential for the treatment of addiction.

Other nonpharmacological strategies include peripheral nerve stimulation and neurofeedback strategies. An example of a peripheral nerve stimulator is the BRIDGE, an FDA-approved device for the treatment of pain, which is being explored as a treatment to reduce opioid withdrawal symptoms and facilitate induction on opioid use disorder medications (174). Neurofeedback strategies train patients to regulate their own brain activity using real-time feedback from functional magnetic resonance imaging or EEG. These strategies can be used in combination with behavioral interventions to help improve executive function in addicted individuals (175). A few small studies have found positive results with EEG neurofeedback in individuals with alcohol and cocaine use disorder (176, 177). Although these treatments are still in their infancy, these studies are promising and may lead to treatment advances.

Behavioral therapies. There is also a significant body of research describing the efficacy of behavioral interventions for substance use disorder. Currently, these represent the only interventions available to treat stimulant, cannabis, and hallucinogen use disorders. Understanding the neurobiological mechanisms that underlie their efficacy is important for guiding the refinement of behavioral treatment strategies.

THE PROMISE OF BASIC RESEARCH

Basic research is the foundation for future advancements in addiction prevention and treatment. A sustained focus in this area will help researchers define the pathways from gene variation to molecular profile, neuron function, brain-circuit activity, and ultimately to disordered behavior, revealing new targets for prevention and treatment interventions.

While research in animal models has contributed to the development of medications for alcohol, opioid, and tobacco use disorders, it often fails to predict efficacy in clinical trials. This may reflect the reliance on abstinence as the primary

endpoint in clinical trials for substance use disorder. The use of alternative outcomes may lead to greater correlation of findings. In parallel, researchers are incorporating more complex social environments into experiments testing medications in animal models that might increase their predictive validity.

The prevention and treatment of substance use disorders would also benefit from biomarkers to help classify individuals into biologically based categories that are reproducible and have predictive validity (178). Biomarkers for the detection of drug exposures in body fluids are valuable but can be used to corroborate only acute or relatively recent drug use. Thus, research is needed to develop and validate biomarkers that reflect chronic drug exposure and that predict disease trajectories and treatment responses. Advances in genetic, epigenetic, and brain imaging tools and technologies offer unprecedented opportunities for the development of such biomarkers.

The same neuroimaging tools that have expanded our understanding of the structural and functional deficits underlying addiction may one day be deployed to monitor, optimize, and personalize addiction treatment (175). An individual's environment, experience, and biology combine to determine his or her risk for developing a substance use disorder, the trajectory the substance use disorder will take, and the interventions that will be most effective for treating it. Large, national investments in basic research, including the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative (179), the Adolescent Brain Cognitive Development study (74), and the Precision Medicine Initiative (180), a prospective study that aims to genotype and phenotype one million Americans, are poised to bridge the gap between neuroscience, genetics, behavioral research, and personalized interventions for the prevention and treatment of substance use disorder.

CONCLUSIONS

Scientific advances have revolutionized our understanding of the biological and psychosocial drivers of addiction. There is tremendous potential to translate this vast knowledge base into meaningful advances in the prevention and treatment of substance use disorder that will benefit not only addiction medicine but the multiplicity of health conditions that are triggered or exacerbated by drug use (181).

AUTHOR AND ARTICLE INFORMATION

From the National Institute on Drug Abuse, NIH, Bethesda, Md.

Address correspondence to Dr. Volkow (nvolkow@nida.nih.gov).

The authors report no financial relationships with commercial interests.

Received Oct. 29, 2017; revision received Feb. 4, 2018; accepted Feb. 5, 2018; published online Apr. 25, 2018.

REFERENCES

1. Hedegaard H, Warner M, Miniño AM: Drug Overdose Deaths in the United States, 1999–2016. National Center for Health Statistics Data Brief No. 294, December 2017. <https://www.cdc.gov/nchs/products/databriefs/db294.htm>

2. Stahre M, Roeber J, Kanny D, et al: Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. *Prev Chronic Dis* 2014; 11:E109
3. National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, Centers for Disease Control and Prevention, 2014
4. Weiss AJ, Bailey MK, O'Malley L, et al: Patient Characteristics of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2014. Rockville, Md, Agency for Healthcare Research and Quality, 2017, p 224
5. Patrick SW, Davis MM, Lehmann CU, et al: Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol* 2015; 35:650-655
6. Centers for Disease Control and Prevention: Fetal Alcohol Spectrum Disorders (FASDs). <https://www.cdc.gov/ncbddd/fasd/data.html>
7. Centers for Disease Control and Prevention: Surveillance for Viral Hepatitis: United States, 2014. <https://www.cdc.gov/hepatitis/statistics/2014surveillance/commentary.htm>
8. Sacks JJ, Gonzales KR, Bouchery EE, et al: 2010 national and state costs of excessive alcohol consumption. *Am J Prev Med* 2015; 49:e73-e79
9. National Drug Intelligence Center, US Department of Justice: The Economic Impact of Illicit Drug Use on American Society: 2011. <https://www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf>
10. Volkow N, Li T-K: The neuroscience of addiction. *Nat Neurosci* 2005; 8:1429-1430
11. Yu C, McClellan J: Genetics of substance use disorders. *Child Adolesc Psychiatr Clin N Am* 2016; 25:377-385
12. Etter JF, Hoda JC, Perroud N, et al: Association of genes coding for the alpha-4, alpha-5, beta-2, and beta-3 subunits of nicotinic receptors with cigarette smoking and nicotine dependence. *Addict Behav* 2009; 34:772-775
13. Bierut LJ, Madden PA, Breslau N, et al: Novel genes identified in a high-density genome-wide association study for nicotine dependence. *Hum Mol Genet* 2007; 16:24-35
14. Görlich A, Antolin-Fontes B, Ables JL, et al: Reexposure to nicotine during withdrawal increases the pacemaking activity of cholinergic habenular neurons. *Proc Natl Acad Sci USA* 2013; 110:17077-17082
15. Koukoulis F, Rooy M, Tziotis D, et al: Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. *Nat Med* 2017; 23:347-354
16. Nestler EJ: Epigenetic mechanisms of drug addiction. *Neuropharmacology* 2014; 76 Pt B:259-268
17. Doura MB, Unterwald EM: MicroRNAs modulate interactions between stress and risk for cocaine addiction. *Front Cell Neurosci* 2016; 10:125
18. Watson CT, Szutorisz H, Garg P, et al: Genome-wide DNA methylation profiling reveals epigenetic changes in the rat nucleus accumbens associated with cross-generational effects of adolescent THC exposure. *Neuropsychopharmacology* 2015; 40:2993-3005
19. Vassoler FM, Oliver DJ, Wyse C, et al: Transgenerational attenuation of opioid self-administration as a consequence of adolescent morphine exposure. *Neuropharmacology* 2017; 113(Pt A):271-280
20. Giedd JN: The teen brain: insights from neuroimaging. *J Adolesc Health* 2008; 42:335-343
21. Jordan CJ, Andersen SL: Sensitive periods of substance abuse: early risk for the transition to dependence. *Dev Cogn Neurosci* 2017; 25:29-44
22. Whitaker LR, Degoulet M, Morikawa H: Social deprivation enhances VTA synaptic plasticity and drug-induced contextual learning. *Neuron* 2013; 77:335-345
23. Eiland L, Romeo RD: Stress and the developing adolescent brain. *Neuroscience* 2013; 249:162-171
24. Lewis CR, Olive MF: Early-life stress interactions with the epigenome: potential mechanisms driving vulnerability toward psychiatric illness. *Behav Pharmacol* 2014; 25:341-351
25. Govindan RM, Behen ME, Helder E, et al: Altered water diffusivity in cortical association tracts in children with early deprivation identified with Tract-Based Spatial Statistics (TBSS). *Cereb Cortex* 2010; 20:561-569
26. Sheridan MA, Fox NA, Zeanah CH, et al: Variation in neural development as a result of exposure to institutionalization early in childhood. *Proc Natl Acad Sci USA* 2012; 109:12927-12932
27. Jasinska AJ, Stein EA, Kaiser J, et al: Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. *Neurosci Biobehav Rev* 2014; 38:1-16
28. Bickel WK, Jarmolowicz DP, Mueller ET, et al: Are executive function and impulsivity antipodes? A conceptual reconstruction with special reference to addiction. *Psychopharmacology (Berl)* 2012; 221:361-387
29. Holmes AJ, Hollinshead MO, Roffman JL, et al: Individual differences in cognitive control circuit anatomy link sensation seeking, impulsivity, and substance use. *J Neurosci* 2016; 36:4038-4049
30. Cheng GLF, Liu Y-P, Chan CCH, et al: Neurobiological underpinnings of sensation seeking trait in heroin abusers. *Eur Neuropharmacol* 2015; 25:1968-1980
31. Sinha R: Chronic stress, drug use, and vulnerability to addiction. *Ann N Y Acad Sci* 2008; 1141:105-130
32. Volkow ND, Koob GF, McLellan AT: Neurobiologic advances from the brain disease model of addiction. *N Engl J Med* 2016; 374:363-371
33. Di Chiara G: Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. *Behav Brain Res* 2002; 137:75-114
34. Volkow ND, Baler RD: NOW vs LATER brain circuits: implications for obesity and addiction. *Trends Neurosci* 2015; 38:345-352
35. Willuhn I, Burgeno LM, Groblewski PA, et al: Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. *Nat Neurosci* 2014; 17:704-709
36. Trantham-Davidson H, Chandler LJ: Alcohol-induced alterations in dopamine modulation of prefrontal activity. *Alcohol* 2015; 49:773-779
37. Volkow ND, Wang G-J, Fowler JS, et al: Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit. *BioEssays* 2010; 32:748-755
38. Lovinger DM: Neurobiological basis of drug reward and reinforcement, in *Addiction Medicine: Science and Practice*. Edited by Johnson BA. New York, Springer, 2011, pp 255-281
39. Koob GF, Le Moal M: Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. *Nat Neurosci* 2005; 8:1442-1444
40. Batalla A, Homberg JR, Lipina TV, et al: The role of the habenula in the transition from reward to misery in substance use and mood disorders. *Neurosci Biobehav Rev* 2017; 80:276-285
41. Volkow ND, Morales M: The brain on drugs: from reward to addiction. *Cell* 2015; 162:712-725
42. Volkow ND, Wang GJ, Telang F, et al: Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. *J Neurosci* 2006; 26:6583-6588
43. Volkow ND, Wang GJ, Ma Y, et al: Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. *J Neurosci* 2005; 25:3932-3939
44. Robbins TW, Ersche KD, Everitt BJ: Drug addiction and the memory systems of the brain. *Ann N Y Acad Sci* 2008; 1141:1-21
45. Kalivas PW, Volkow ND: New medications for drug addiction hiding in glutamatergic neuroplasticity. *Mol Psychiatry* 2011; 16:974-986
46. Park PE, Schlosburg JE, Vendruscolo LF, et al: Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. *Addict Biol* 2015; 20:275-284
47. Schlosburg JE, Whitfield TW Jr, Park PE, et al: Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake. *J Neurosci* 2013; 33:19384-19392

48. Kessler RC: The epidemiology of dual diagnosis. *Biol Psychiatry* 2004; 56:730-737
49. Kelly TM, Daley DC: Integrated treatment of substance use and psychiatric disorders. *Soc Work Public Health* 2013; 28:388-406
50. Ross S, Peselow E: Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. *Clin Neuropharmacol* 2012; 35:235-243
51. Torrens M, Rossi PC, Martinez-Riera R, et al: Psychiatric comorbidity and substance use disorders: treatment in parallel systems or in one integrated system? *Subst Use Misuse* 2012; 47: 1005-1014
52. Wing VC, Wass CE, Soh DW, et al: A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. *Ann N Y Acad Sci* 2012; 1248: 89-106
53. Tsuang MT, Francis T, Minor K, et al: Genetics of smoking and depression. *Hum Genet* 2012; 131:905-915
54. Howes OD, Fusar-Poli P, Bloomfield M, et al: From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. *Curr Pharm Des* 2012; 18: 459-465
55. Volkow ND, Fowler JS, Wang GJ, et al: Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. *Arch Neurol* 2007; 64:1575-1579
56. Xing B, Li YC, Gao WJ: Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. *Brain Res* 2016; 1641(Pt B):217-233
57. Marazziti D: Understanding the role of serotonin in psychiatric diseases. *F1000 Res* 2017; 6:180
58. Müller CP, Homberg JR: The role of serotonin in drug use and addiction. *Behav Brain Res* 2015; 277:146-192
59. Tsapakis EM: Glutamate and psychiatric disorders. *Adv Psychiatr Treat* 2002; 8:189-197
60. Tzschentke TM, Schmidt WJ: Glutamatergic mechanisms in addiction. *Mol Psychiatry* 2003; 8:373-382
61. Kumar K, Sharma S, Kumar P, et al: Therapeutic potential of GABA (B) receptor ligands in drug addiction, anxiety, depression, and other CNS disorders. *Pharmacol Biochem Behav* 2013; 110:174-184
62. Aston-Jones G, Kalivas PW: Brain norepinephrine rediscovered in addiction research. *Biol Psychiatry* 2008; 63:1005-1006
63. Langer SZ: α 2-Adrenoceptors in the treatment of major neuropsychiatric disorders. *Trends Pharmacol Sci* 2015; 36:196-202
64. Enoch MA: The influence of gene-environment interactions on the development of alcoholism and drug dependence. *Curr Psychiatry Rep* 2012; 14:150-158
65. US Department of Health and Human Services: Surgeon General's Report on Alcohol, Drugs, and Health, 2016. <https://addiction.surgeongeneral.gov>
66. Ersche KD, Jones PS, Williams GB, et al: Abnormal brain structure implicated in stimulant drug addiction. *Science* 2012; 335:601-604
67. Moffitt TE, Arseneault L, Belsky D, et al: A gradient of childhood self-control predicts health, wealth, and public safety. *Proc Natl Acad Sci USA* 2011; 108:2693-2698
68. Diamond A, Lee K: Interventions shown to aid executive function development in children 4 to 12 years old. *Science* 2011; 333:959-964
69. Wiers CE, Shokri-Kojori E, Cabrera E, et al: Socioeconomic status is associated with striatal dopamine D2/D3 receptors in healthy volunteers but not in cocaine abusers. *Neurosci Lett* 2016; 617:27-31
70. Morgan D, Grant KA, Gage HD, et al: Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. *Nat Neurosci* 2002; 5:169-174
71. Martinez D, Orłowska D, Narendran R, et al: Dopamine type 2/3 receptor availability in the striatum and social status in human volunteers. *Biol Psychiatry* 2010; 67:275-278
72. Zalesky A, Solowij N, Yücel M, et al: Effect of long-term cannabis use on axonal fibre connectivity. *Brain* 2012; 135:2245-2255
73. Squeglia LM, Tapert SF, Sullivan EV, et al: Brain development in heavy-drinking adolescents. *Am J Psychiatry* 2015; 172:531-542
74. Adolescent Brain Cognitive Development Study. <https://abcdstudy.org>
75. Foundation for the National Institutes of Health: Baby Connectome Project. <https://fnih.org/what-we-do/current-research-programs/baby-connectome>
76. Braeburn Pharmaceuticals: FDA Acceptance of NDA for CAM2038 for Opioid Use Disorder, 2017. <https://www.braeburn-pharmaceuticals.com/fda-acceptance-of-nda-for-cam2038-for-opioid-use-disorder/>
77. Klein JW: Pharmacotherapy for substance use disorders. *Med Clin North Am* 2016; 100:891-910
78. National Institute on Drug Abuse, National Institutes of Health: Principles of Drug Addiction Treatment: A Research Based Guide (Third Edition), 2012. <https://www.drugabuse.gov/publications/principles-drug-addiction-treatment/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies>
79. Institute of Medicine: The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC, National Academy Press, 1995
80. Center for Drug Evaluation and Research, US Food and Drug Administration: Alcoholism: Developing Drugs for Treatment: Guidance for Industry, 2015. <https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm433618.pdf>
81. National Institute on Drug Abuse, National Institutes of Health: Problems of Drug Dependence, 1998: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, 1998. http://rzbl04.biblio.etc.tu-bs.de:8080/docportal/servlets/MCRFileNodeServlet/DocPortal_derivate_00001868/NIDA179.pdf
82. National Institute on Drug Abuse, National Institutes of Health: Probuphine: A Game-Changer in Fighting Opioid Dependence, 2016. <https://www.drugabuse.gov/about-nida/noras-blog/2016/05/probuphine-game-changer-in-fighting-opioid-dependence>
83. National Institute on Drug Abuse, National Institutes of Health: NARCAN Nasal Spray: Life-saving Science at NIDA, 2015. <https://www.drugabuse.gov/about-nida/noras-blog/2015/11/narcan-nasal-spray-life-saving-science-nida>
84. Volkow ND, Collins FS: The role of science in addressing the opioid crisis. *N Engl J Med* 2017; 377:391-394
85. Brady KT, Gray KM, Tolliver BK: Cognitive enhancers in the treatment of substance use disorders: clinical evidence. *Pharmacol Biochem Behav* 2011; 99:285-294
86. Sofuoglu M, DeVito EE, Waters AJ, et al: Cognitive enhancement as a treatment for drug addictions. *Neuropharmacology* 2013; 64:452-463
87. Sofuoglu M, DeVito EE, Waters AJ, et al: Cognitive function as a transdiagnostic treatment target in stimulant use disorders. *J Dual Diagn* 2016; 12:90-106
88. Verplaetse TL, McKee SA: Targeting stress neuroadaptations for addiction treatment: a commentary on Kaye et al. (2017). *J Stud Alcohol Drugs* 2017; 78:372-374
89. Carroll FI, Carlezon WA Jr: Development of κ opioid receptor antagonists. *J Med Chem* 2013; 56:2178-2195
90. Lee HM, Kim Y: Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders. *Schizophr Res Treatment* 2016; 2016:6378137
91. Goldstein MG: Bupropion sustained release and smoking cessation. *J Clin Psychiatry* 1998; 59(Suppl 4):66-72
92. Ling W, Hillhouse MP, Saxon AJ, et al: Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. *Addiction* 2016; 111:1416-1427
93. Gerra G, Fantoma A, Zaimovic A: Naltrexone and buprenorphine combination in the treatment of opioid dependence. *J Psychopharmacol* 2006; 20:806-814
94. Haney M, Hart CL, Vosburg SK, et al: Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. *Psychopharmacology (Berl)* 2008; 197:157-168

95. Negus SS, Henningfield J: Agonist medications for the treatment of cocaine use disorder. *Neuropsychopharmacology* 2015; 40:1815–1825
96. Lai H, Stitzer M, Treisman G, et al: Cocaine abstinence and reduced use associated with lowered marker of endothelial dysfunction in African Americans: a preliminary study. *J Addict Med* 2015; 9: 331–339
97. Falk D, Wang XQ, Liu L, et al: Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. *Alcohol Clin Exp Res* 2010; 34:2022–2034
98. Lee JD, Friedmann PD, Kinlock TW, et al: Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *N Engl J Med* 2016; 374:1232–1242
99. Huang W, Manglik A, Venkatakrishnan AJ, et al: Structural insights into μ -opioid receptor activation. *Nature* 2015; 524:315–321
100. DeWire SM, Yamashita DS, Rominger DH, et al: A G protein-biased ligand at the μ -opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. *J Pharmacol Exp Ther* 2013; 344:708–717
101. Singla N, Minkowitz H, Soergel D, et al: (432) Respiratory safety signal with oliceridine (TRV130), a novel mu receptor G protein pathway selective modulator (mu-GPS), vs morphine: a safety analysis of a phase 2b randomized clinical trial. *J Pain* 2016; 17:S82
102. Ding H, Czoty PW, Kiguchi N, et al: A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. *Proc Natl Acad Sci USA* 2016; 113:E5511–E5518
103. Günther T, Dasgupta P, Mann A, et al: Targeting multiple opioid receptors: improved analgesics with reduced side effects? *Br J Pharmacol* (Epub ahead of print, Apr 5, 2017)
104. Sandweiss AJ, Vanderah TW: The pharmacology of neurokinin receptors in addiction: prospects for therapy. *Subst Abuse Rehabil* 2015; 6:93–102
105. US WorldMeds LLC: Open-Label, Safety Study of Lofexidine. <https://clinicaltrials.gov/ct2/show/NCT02363998>
106. Gerra G, Zaimovic A, Giusti F, et al: Lofexidine versus clonidine in rapid opiate detoxification. *J Subst Abuse Treat* 2001; 21:11–17
107. Neelakantan H, Holliday ED, Fox RG, et al: Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. *ACS Chem Neurosci* 2017; 8:1065–1073
108. Peris J, MacFadyen K, Smith JA, et al: Oxytocin receptors are expressed on dopamine and glutamate neurons in the mouse ventral tegmental area that project to nucleus accumbens and other mesolimbic targets. *J Comp Neurol* 2017; 525:1094–1108
109. Meyer-Lindenberg A, Domes G, Kirsch P, et al: Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat Rev Neurosci* 2011; 12:524–538
110. Kovács CL, Van Ree JM: Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats. *Life Sci* 1985; 37:1895–1900
111. Leong KC, Zhou L, Ghee SM, et al: Oxytocin decreases cocaine taking, cocaine seeking, and locomotor activity in female rats. *Exp Clin Psychopharmacol* 2016; 24:55–64
112. Bentzley BS, Zhou TC, Aston-Jones G: Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat. *Proc Natl Acad Sci USA* 2014; 111:11822–11827
113. Cox BM, Bentzley BS, Regen-Tuero H, et al: Oxytocin acts in nucleus accumbens to attenuate methamphetamine seeking and demand. *Biol Psychiatry* 2017; 81:949–958
114. MacFadyen K, Loveless R, DeLuca B, et al: Peripheral oxytocin administration reduces ethanol consumption in rats. *Pharmacol Biochem Behav* 2016; 140:27–32
115. Peters ST, Bowen MT, Bohrer K, et al: Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens. *Addict Biol* 2017; 22:702–711
116. King CE, Griffin WC, Luderan LN, et al: Oxytocin reduces ethanol self-administration in mice. *Alcohol Clin Exp Res* 2017; 41:955–964
117. Manbeck KE, Shelley D, Schmidt CE, et al: Effects of oxytocin on nicotine withdrawal in rats. *Pharmacol Biochem Behav* 2014; 116:84–89
118. Hicks C, Cornish JL, Baracz SJ, et al: Adolescent pre-treatment with oxytocin protects against adult methamphetamine-seeking behavior in female rats. *Addict Biol* 2016; 21:304–315
119. Bowen MT, Carson DS, Spiro A, et al: Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. *PLoS One* 2011; 6:e27237
120. Carson DS, Cornish JL, Guastella AJ, et al: Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. *Neuropharmacology* 2010; 58:38–43
121. Cox BM, Young AB, See RE, et al: Sex differences in methamphetamine seeking in rats: impact of oxytocin. *Psychoneuroendocrinology* 2013; 38:2343–2353
122. Ferland CL, Reichel CM, McGinty JF: Effects of oxytocin on methamphetamine-seeking exacerbated by predator odor pre-exposure in rats. *Psychopharmacology (Berl)* 2016; 233:1015–1024
123. Zhou L, Sun WL, Young AB, et al: Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function. *Int J Neuropsychopharmacol* 2015; 18:pyu009
124. Morales-Rivera A, Hernández-Burgos MM, Martínez-Rivera A, et al: Anxiolytic effects of oxytocin in cue-induced cocaine seeking behavior in rats. *Psychopharmacology (Berl)* 2014; 231:4145–4155
125. Miller MA, Bershad A, King AC, et al: Intranasal oxytocin dampens cue-elicited cigarette craving in daily smokers: a pilot study. *Behav Pharmacol* 2016; 27:697–703
126. McRae-Clark AL, Baker NL, Maria MM, et al: Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. *Psychopharmacology (Berl)* 2013; 228:623–631
127. Levin FR, Mariani JJ, Brooks DJ, et al: Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend* 2011; 116:142–150
128. Haney M, Cooper ZD, Bedi G, et al: Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. *Neuropsychopharmacology* 2013; 38:1557–1565
129. Allsop DJ, Copeland J, Lintzeris N, et al: Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. *JAMA Psychiatry* 2014; 71:281–291
130. GW Pharmaceuticals: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol), Mar 14, 2016. <https://www.gvpharm.com/about-us/news/gw-pharmaceuticals-announces-positive-phase-3-pivotal-study-results-epidiolex>
131. den Boon FS, Werkman TR, Schaafsma-Zhao Q, et al: Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex. *Pflugers Arch* 2015; 467:1551–1564
132. Sam AH, Salem V, Ghatei MA: Rimonabant: from RIO to ban. *J Obes* 2011; 2011:432607
133. Khajehali E, Malone DT, Glass M, et al: Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. *Mol Pharmacol* 2015; 88:368–379
134. Vallée M, Vitiello S, Bellocchio L, et al: Pregnenolone can protect the brain from cannabis intoxication. *Science* 2014; 343:94–98
135. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, et al: A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. *Neuropsychopharmacology* 2015; 40:2948–2959
136. Schlosburg JE, Carlson BLA, Ramesh D, et al: Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. *AAPS J* 2009; 11:342–352
137. Kinsey SG, Long JZ, O'Neal ST, et al: Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. *J Pharmacol Exp Ther* 2009; 330:902–910
138. Castells X, Cunill R, Pérez-Mañá C, et al: Psychostimulant drugs for cocaine dependence. *Cochrane Database Syst Rev* 2016; 9:CD007380
139. Volkow ND, Fowler JS, Logan J, et al: Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. *JAMA* 2009; 301:1148–1154

140. Kampman KM, Lynch KG, Pettinati HM, et al: A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. *Drug Alcohol Depend* 2015; 155:105–110
141. Sangroula D, Motiwala F, Wagle B, et al: Modafinil treatment of cocaine dependence: a systematic review and meta-analysis. *Subst Use Misuse* 2017; 52:1292–1306
142. Kauer JA, Malenka RC: Synaptic plasticity and addiction. *Nat Rev Neurosci* 2007; 8:844–858
143. Moussawi K, Pacchioni A, Moran M, et al: N-Acetylcysteine reverses cocaine-induced metaplasticity. *Nat Neurosci* 2009; 12:182–189
144. Reichel CM, See RE: Chronic N-acetylcysteine after cocaine self-administration produces enduring reductions in drug-seeking. *Neuropsychopharmacology* 2012; 37:298
145. LaRowe SD, Mardikian P, Malcolm R, et al: Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. *Am J Addict* 2006; 15:105–110
146. LaRowe SD, Kalivas PW, Nicholas JS, et al: A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. *Am J Addict* 2013; 22:443–452
147. Ghitza UE: Needed relapse-prevention research on novel framework (ASPIRE model) for substance use disorders treatment. *Front Psychiatry* 2015; 6:37
148. Brim RL, Nance MR, Youngstrom DW, et al: A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. *Mol Pharmacol* 2010; 77:593–600
149. Chen X, Zheng X, Zhou Z, et al: Effects of a cocaine hydrolase engineered from human butyrylcholinesterase on metabolic profile of cocaine in rats. *Chem Biol Interact* 2016; 259(Pt B):104–109
150. Chen X, Xue L, Hou S, et al: Long-acting cocaine hydrolase for addiction therapy. *Proc Natl Acad Sci USA* 2016; 113:422–427
151. Zheng X, Zhou Z, Zhang T, et al: Effectiveness of a cocaine hydrolase for cocaine toxicity treatment in male and female rats. *AAPS J* 2017; 20:3
152. Gilgun-Sherki Y, Eliaz RE, McCann DJ, et al: Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. *Drug Alcohol Depend* 2016; 166:13–20
153. Wood SK, Narasimhan D, Cooper Z, et al: Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. *Drug Alcohol Depend* 2010; 106:219–229
154. Zheng F, Zhan C-G: Enzyme-therapy approaches for the treatment of drug overdose and addiction. *Future Med Chem* 2011; 3:9–13
155. Dewey SL, Morgan AE, Ashby CR Jr, et al: A novel strategy for the treatment of cocaine addiction. *Synapse* 1998; 30:119–129
156. Volkow ND, Wang GJ, Fowler JS, et al: Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study. *Am J Psychiatry* 1998; 155:200–206
157. Leung JG, Hall-Flavin D, Nelson S, et al: The role of gabapentin in the management of alcohol withdrawal and dependence. *Ann Pharmacother* 2015; 49:897–906
158. Shinn AK, Greenfield SF: Topiramate in the treatment of substance-related disorders: a critical review of the literature. *J Clin Psychiatry* 2010; 71:634–648
159. Johnson BA, Ait-Daoud N, Wang XQ, et al: Topiramate for the treatment of cocaine addiction: a randomized clinical trial. *JAMA Psychiatry* 2013; 70:1338–1346
160. Elkashef A, Kahn R, Yu E, et al: Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. *Addiction* 2012; 107:1297–1306
161. Pravetoni M, Le Naour M, Tucker AM, et al: Reduced anti-nociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. *J Med Chem* 2013; 56:915–923
162. Bremer PT, Schlosburg JE, Lively JM, et al: Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. *Mol Pharm* 2014; 11:1075–1080
163. Bremer PT, Kimishima A, Schlosburg JE, et al: Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. *Angew Chem Int Ed Engl* 2016; 55:3772–3775
164. Lockner JW, Eubanks LM, Choi JL, et al: Flagellin as carrier and adjuvant in cocaine vaccine development. *Mol Pharm* 2015; 12:653–662
165. Kimishima A, Wenthur CJ, Eubanks LM, et al: Cocaine vaccine development: evaluation of carrier and adjuvant combinations that activate multiple toll-like receptors. *Mol Pharm* 2016; 13:3884–3890
166. Raupach T, Hoogsteder PHJ, Onno van Schayck CP: Nicotine vaccines to assist with smoking cessation: current status of research. *Drugs* 2012; 72:e1–e16
167. Stevens MW, Henry RL, Owens SM, et al: First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. *Mabs* 2014; 6:1649–1656
168. Research Portfolio Online Reporting Tools, National Institutes of Health: Advancing the development of a humanized anti-cocaine monoclonal antibody: project number 5U01DA039550-03. https://projectreporter.nih.gov/project_info_description.cfm?aid=9274949&icde=35785903
169. Research Portfolio Online Reporting Tools, National Institutes of Health: Lead optimization and preclinical development of human nicotine-specific mAbs: project number 5R01DA038877-03. https://projectreporter.nih.gov/project_info_description.cfm?aid=9113552&icde=35785854
170. Kimishima A, Wenthur CJ, Zhou B, et al: An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life. *ACS Chem Biol* 2017; 12:36–40
171. Terraneo A, Leggio L, Saladini M, et al: Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study. *Eur Neuropsychopharmacol* 2016; 26:37–44
172. Grall-Bronnec M, Sauvaget A: The use of repetitive transcranial magnetic stimulation for modulating craving and addictive behaviours: a critical literature review of efficacy, technical and methodological considerations. *Neurosci Biobehav Rev* 2014; 47:592–613
173. Lupi M, Martinotti G, Santacroce R, et al: Transcranial direct current stimulation in substance use disorders: a systematic review of scientific literature. *J ECT* 2017; 33:203–209
174. Miranda A, Taca A: Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. *Am J Drug Alcohol Abuse* 2017; 44:56–63
175. Zilverstand A, Parvaz MA, Moeller SJ, et al: Cognitive interventions for addiction medicine: understanding the underlying neurobiological mechanisms. *Prog Brain Res* 2016; 224:285–304
176. Cox WM, Subramanian L, Linden DEJ, et al: Neurofeedback training for alcohol dependence versus treatment as usual: study protocol for a randomized controlled trial. *Trials* 2016; 17:480
177. Horrell T, El-Baz A, Baruth J, et al: Neurofeedback effects on evoked and induced EEG gamma band reactivity to drug-related cues in cocaine addiction. *J Neurother* 2010; 14:195–216
178. Volkow ND, Koob G, Baler R: Biomarkers in substance use disorders. *ACS Chem Neurosci* 2015; 6:522–525
179. National Institutes of Health: Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. <https://www.braininitiative.nih.gov>
180. National Institutes of Health: Precision Medicine Initiative. <https://allofus.nih.gov>
181. Schulte MT, Hser Y-I: Substance use and associated health conditions throughout the lifespan. *Public Health Rev* 2014; 35:2